Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.660
+0.110 (7.10%)
May 27, 2025, 3:26 PM - Market open
Editas Medicine Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Editas Medicine stock ranges from a low of $3.00 to a high of $15. The average analyst price target of $6.73 forecasts a 305.42% increase in the stock price over the next year.
Price Target: $6.73 (+305.42%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 7 | 7 | 7 | 7 | 7 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 15 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +140.96% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +80.72% | Apr 28, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +201.20% | Dec 16, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Dec 16, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +140.96% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
10.08M
from 32.31M
Decreased by -68.82%
Revenue Next Year
7.00M
from 10.08M
Decreased by -30.52%
EPS This Year
-1.74
from -2.88
EPS Next Year
-1.14
from -1.74
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.1M | 22.6M | 26.3M | ||
| Avg | 10.1M | 7.0M | 8.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.5% | 124.0% | 274.9% | ||
| Avg | -68.8% | -30.5% | 25.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.27 | -0.78 | -0.57 | ||
| Avg | -1.74 | -1.14 | -1.13 | ||
| Low | -2.07 | -1.74 | -1.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.